Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Study: Vasodilators first choice for some heart patients

05.07.2005


Few front-line medications exist for treating hospitalized patients with acute decompensated heart failure, a stage of heart failure marked by heightened severity and often-lengthy hospital stays with frequent readmissions. Now, a study suggests the list of preferred drugs for treating the disease might be even shorter.



In a study released today (7/5) in the Journal of the American College of Cardiology, researchers found that two particular drugs were associated with substantially lower in-hospital mortality than two other drugs that also are commonly used for treating patients with acute decompensated heart failure (ADHF).

The retrospective study draws from a multi-institutional registry of 65,180 patients with ADHF. In comparisons of patients treated intravenously with nitroglycerin, nesiritide, dobutamine or milrinone, there was a lower in-hospital mortality rate for patients administered nitroglycerin or nesiritide than the drugs dobutamine or milrinone.


According to Dr. William T. Abraham, lead author of the study and director of cardiovascular medicine at the Richard M. Ross Heart Hospital at The Ohio State University, the findings may surprise some in the medical community, particularly those who favor the use of positive inotropes, the group of drugs that includes dobutamine and milrinone.

"This is a significant finding from a large population of patients and will certainly aid in the development of guidelines for treating patients with acute decompensated heart failure," said Abraham.

Congestive heart failure is characterized by a progressive loss in the heart’s ability to pump blood. When a patient’s condition suddenly or rapidly deteriorates to the point that hospitalization is required, the patient is described as having experienced acute heart failure or acute decompensated heart failure.

Positive inotropes increase the pumping action of the heart, while nitroglycerin and nesiritide act as vasodilators, causing the blood vessels to dilate and reducing the amount of effort needed by the heart to pump blood to the body.

For the study, 15,230 patients in the registry received one or more of the four drugs. Nitroglycerin was given to 6,549 patients, nesiritide, 5,220; milrinone, 2,021; and dobutamine, 4,226. The therapies administered were based on clinician judgment, not on a randomized protocol. Another 49,950 patients in the registry did not receive any of the four drugs, presumably because their heart failure was less severely worsened.

After adjusting for differences in patient characteristics, mortality was similar for patients given nitroglycerin or nesiritide, while patients given milrinone or dobutamine experienced an approximately 35 percent to 50 percent increase in the chance of dying in the hospital. Between the latter two agents, dobutamine was associated with higher in-hospital mortality than milrinone.

"Our study suggests that inotropes be reserved for patients who fail with vasodilators or are so severely ill that vasodilators alone are likely to be inadequate treatment," said Abraham, also associate director for clinical/translational research at Ohio State’s Davis Heart and Lung Research Institute.

Abraham stresses that nitroglycerin and nesiritide appear to be equally safe in the treatment of ADHF and that other criteria should be considered when choosing between the two drugs.

People with this life-threatening degree of heart failure are usually treated in a hospital setting due to the severity of their illness and the intensity of their treatment. While guidelines exist for treating outpatients with chronic heart failure, a lack of statistical data has prevented similar guidelines from being established for ADHF.

Creation in 2001 of the Acute Decompensated Heart Failure National Registry (ADHERE) has helped coordinate and expedite the collection of data from more than 275 hospitals from across the country. The registry is the first of its kind to gather detailed information about patients with ADHF. Patients with a primary diagnosis of heart failure admitted to any of the participating hospitals are entered in the registry. Data for the study was taken from patients treated from late 2001 to mid-2003.

Acute heart failure is the leading cause of hospitalization in persons over age 65 years of age and accounts for approximately 1 million hospital admissions each year in the United States.

David Crawford | EurekAlert!
Further information:
http://www.osu.edu

More articles from Studies and Analyses:

nachricht New study from the University of Halle: How climate change alters plant growth
12.01.2018 | Martin-Luther-Universität Halle-Wittenberg

nachricht Disarray in the brain
18.12.2017 | Universität zu Lübeck

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

Im Focus: A thermometer for the oceans

Measurement of noble gases in Antarctic ice cores

The oceans are the largest global heat reservoir. As a result of man-made global warming, the temperature in the global climate system increases; around 90% of...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

White graphene makes ceramics multifunctional

16.01.2018 | Materials Sciences

Breaking bad metals with neutrons

16.01.2018 | Materials Sciences

ISFH-CalTeC is “designated test centre” for the confirmation of solar cell world records

16.01.2018 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>